|Articles|November 27, 2018
OmniComm’s TrialMaster® EDC Selected for Multi-Study Cancer Research
Advertisement
An international biopharmaceutical company has signed a multiyear agreement with OmniComm Systems, Inc. in which the company will use OmniComm’s TrialMaster EDC technology to develop clinical studies at multiple research sites to test a cancer treatment.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Confidence Trap in Clinical Trials: When Knowing Just Enough Becomes Dangerous
2
Redefining CRA Workflows Through Intelligent Automation
3
Applied Clinical Trials' 2025 State of the Industry Survey
4
Beyond the Comment Section: Rebuilding Trust in Vaccines Through Conversation
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
